Voss Capital LP Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Voss Capital LP acquired a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 275,000 shares of the company's stock, valued at approximately $1,510,000. Voss Capital LP owned approximately 0.18% of Xeris Biopharma at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of XERS. Nuveen LLC bought a new position in shares of Xeris Biopharma during the 1st quarter valued at about $12,240,000. Invesco Ltd. lifted its holdings in shares of Xeris Biopharma by 1,387.8% during the 1st quarter. Invesco Ltd. now owns 1,026,838 shares of the company's stock valued at $5,637,000 after purchasing an additional 957,822 shares in the last quarter. Informed Momentum Co LLC lifted its holdings in shares of Xeris Biopharma by 320.3% during the 1st quarter. Informed Momentum Co LLC now owns 934,646 shares of the company's stock valued at $5,131,000 after purchasing an additional 712,269 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of Xeris Biopharma by 36,542.7% during the 1st quarter. Federated Hermes Inc. now owns 687,783 shares of the company's stock valued at $3,776,000 after purchasing an additional 685,906 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Xeris Biopharma by 166.2% during the 4th quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company's stock valued at $3,537,000 after purchasing an additional 651,481 shares in the last quarter. Institutional investors own 42.75% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on XERS. Oppenheimer lifted their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Wall Street Zen upgraded Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Xeris Biopharma in a research note on Tuesday, August 12th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $6.58.

Insiders Place Their Bets

In related news, insider Kevin Mcculloch purchased 25,000 shares of the stock in a transaction on Friday, June 13th. The shares were purchased at an average price of $4.38 per share, with a total value of $109,500.00. Following the transaction, the insider directly owned 1,708,585 shares of the company's stock, valued at $7,483,602.30. This trade represents a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John Johnson sold 107,500 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total value of $786,900.00. Following the transaction, the director directly owned 833,483 shares in the company, valued at $6,101,095.56. This trade represents a 11.42% decrease in their position. The disclosure for this sale can be found here. Insiders own 4.56% of the company's stock.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $7.36 on Tuesday. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -35.05 and a beta of 0.65. The stock's 50 day moving average price is $5.28 and its two-hundred day moving average price is $4.75. Xeris Biopharma Holdings, Inc. has a 52 week low of $2.48 and a 52 week high of $7.79.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analyst estimates of $64.58 million. On average, equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.